Zhong Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhong Huang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bisheng Tan
Institute of Chemical Materials, China Academy of Engineering Physics (CAEP), Mianyang 621900, PR China
2 shared publications - Hui Huang
School of Control Science and Engineering, Dalian University of Technology, Dalian, China
2 shared publications - Xinping Long
Wuhan University
2 shared publications - Xun Han
Institute of Chemical Materials, China Academy of Engineering Physics (CAEP), Mail Box 919, Branch Box 311, Mianyang 621900, P. R. China
2 shared publications Andrew R. Fisher
Department of Obstetrics and Gynecology University of Chicago Chicago Illinois USA
1 shared publicationDeepshika Sudhakar
Pritzker School of Medicine University of Chicago Chicago Illinois USA
1 shared publication
Latest Publications
- 1 August 2023
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 18 (6) , 834-842
Mesenchymal Stem Cell Transplantation For Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe complication with a poor prognosis. Recently, mesenchymal stem cell (MSC)-based therapy for HBVACLF has shown considerable promise. Therefore, this systematic review and meta-analysis aimed to evaluate the efficacy and safety of MSC transplantation for patients with HBV-ACLF. Methods: The PubMed, Cochrane Library, CNKI, and Embase databases were searched from their inception to March 2021 for reports on MSC therapy for HBV-ACLF. We used RevMan 5.3 to perform the systematic review and meta-analysis. Results: Four studies were ultimately included. Compared with the control treatment, allogeneic MSC treatment resulted in a higher cumulative survival rate among ACLF patients (OR=2.27; 95% CI 1.35, 3.81; p=0.002). The umbilical cord-derived MSC (UC-MSC) group obtained a higher survival rate than the control group (OR = 2.33; 95% CI 1.17, 4.63; p=0.02). The group with multiple interval peripheral vein injections of MSCs obtained a higher survival rate than the control group (OR = 2.09; 95% CI 1.20, 3.67; p=0.01). None of the adverse events were MSC-related. Conclusion: Our study indicates that MSC transplantation can significantly increase survival rates by improving liver function without severe adverse events. UC-MSCs harvested for allogeneic infusion via peripheral veins appear to provide superior treatment for patients.
- 1 August 2023
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 18 (6) , 834-842
Mesenchymal Stem Cell Transplantation For Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe complication with a poor prognosis. Recently, mesenchymal stem cell (MSC)-based therapy for HBVACLF has shown considerable promise. Therefore, this systematic review and meta-analysis aimed to evaluate the efficacy and safety of MSC transplantation for patients with HBV-ACLF. Methods: The PubMed, Cochrane Library, CNKI, and Embase databases were searched from their inception to March 2021 for reports on MSC therapy for HBV-ACLF. We used RevMan 5.3 to perform the systematic review and meta-analysis. Results: Four studies were ultimately included. Compared with the control treatment, allogeneic MSC treatment resulted in a higher cumulative survival rate among ACLF patients (OR=2.27; 95% CI 1.35, 3.81; p=0.002). The umbilical cord-derived MSC (UC-MSC) group obtained a higher survival rate than the control group (OR = 2.33; 95% CI 1.17, 4.63; p=0.02). The group with multiple interval peripheral vein injections of MSCs obtained a higher survival rate than the control group (OR = 2.09; 95% CI 1.20, 3.67; p=0.01). None of the adverse events were MSC-related. Conclusion: Our study indicates that MSC transplantation can significantly increase survival rates by improving liver function without severe adverse events. UC-MSCs harvested for allogeneic infusion via peripheral veins appear to provide superior treatment for patients.
- Open Access
- 20 November 2022
- Published by Wiley in Neurourology and Urodynamics
- Vol. 42 (5) , 903-920
Feminizing gender‐affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks
Aims: Feminizing gender‐affirming hormone therapy (GAHT) can be utilized to help transfeminine transgender and gender diverse (TGD) individuals achieve the transformation of outward sex characteristics, thereby leading to improvements in psychological and social well‐being. In this narrative review, we aim to summarize current guidelines for feminizing GAHT management as well as the available literature describing the associated health risks pertaining to cardiovascular disease, thromboembolic disease, bone health, and cancer risks.Methods: Relevant literature from January 2019 through July 2022 pertaining to feminizing GAHT was identified using PubMed, Cochrane Library, EMBASE, and MEDLINE. A narrative summary was performed with the inclusion of more recently published guidance from the World Professional Association for Transgender Health, Standards of Care Version 8.Results: Guidance regarding the prescribing of feminizing GAHT with estrogen, antiandrogen, and progesterone medications is summarized along with considerations of the cardiovascular, thromboembolic, bone health, and cancer risks associated with these therapies.Conclusions: Feminizing GAHT is a highly effective method for transfeminine TGD patients to achieve medically necessary changes in secondary sex characteristics. Knowledge of the health risks of feminizing GAHT is largely drawn from research in the cisgender population, with a growing body of literature in TGD‐specific patient populations. Feminizing GAHT appears to carry a low risk profile for most patients; however, further research describing the risks of hormone management around the time of gender‐affirming surgery and in the aging TGD population is needed to optimize GAHT in the context of the evolving health risks over a TGD patient's lifespan.
- 20 November 2022
- Published by Wiley in Neurourology and Urodynamics
- Vol. 42 (5) , 903-920
Open AccessFeminizing gender‐affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks
Aims: Feminizing gender‐affirming hormone therapy (GAHT) can be utilized to help transfeminine transgender and gender diverse (TGD) individuals achieve the transformation of outward sex characteristics, thereby leading to improvements in psychological and social well‐being. In this narrative review, we aim to summarize current guidelines for feminizing GAHT management as well as the available literature describing the associated health risks pertaining to cardiovascular disease, thromboembolic disease, bone health, and cancer risks.Methods: Relevant literature from January 2019 through July 2022 pertaining to feminizing GAHT was identified using PubMed, Cochrane Library, EMBASE, and MEDLINE. A narrative summary was performed with the inclusion of more recently published guidance from the World Professional Association for Transgender Health, Standards of Care Version 8.Results: Guidance regarding the prescribing of feminizing GAHT with estrogen, antiandrogen, and progesterone medications is summarized along with considerations of the cardiovascular, thromboembolic, bone health, and cancer risks associated with these therapies.Conclusions: Feminizing GAHT is a highly effective method for transfeminine TGD patients to achieve medically necessary changes in secondary sex characteristics. Knowledge of the health risks of feminizing GAHT is largely drawn from research in the cisgender population, with a growing body of literature in TGD‐specific patient populations. Feminizing GAHT appears to carry a low risk profile for most patients; however, further research describing the risks of hormone management around the time of gender‐affirming surgery and in the aging TGD population is needed to optimize GAHT in the context of the evolving health risks over a TGD patient's lifespan.
- 3 December 2021
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 22 (1) , 293-303
Theoretical Calculation of Cocrystal Components for Explosives: A Similarity Function of Energetic Supramolecules
- 3 December 2021
- Published by American Chemical Society (ACS) in Crystal Growth & Design
- Vol. 22 (1) , 293-303
Theoretical Calculation of Cocrystal Components for Explosives: A Similarity Function of Energetic Supramolecules
- 1 November 2021
- Published by Elsevier in Polyhedron
- Vol. 209, 115451
Construction strategies for high-nitrogen M8N60 complexes with high detonation heat and controllable stability
- 1 November 2021
- Published by Elsevier in Polyhedron
- Vol. 209, 115451
Construction strategies for high-nitrogen M8N60 complexes with high detonation heat and controllable stability
- 1 June 2015
- Published by Springer Nature in Interceram - International Ceramic Review
- Vol. 64 (3) , 100-103
Research Progress in Preparation of Porous Ceramics
- 1 June 2015
- Published by Springer Nature in Interceram - International Ceramic Review
- Vol. 64 (3) , 100-103
Research Progress in Preparation of Porous Ceramics